Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

References

• American Thoracic Society/European Respiratory Society Task ForceStandards for the Diagnosis and Management of Patients with COPD 2004New York, NYAmerican Thoracic Society/European Respiratory Society Task Force2005
   Google Scholar
• National Collaborating Centre for Chronic ConditionsChronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary careThorax200459 Suppl 11232
   Google Scholar
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseGlobal Initiative for Chronic Obstructive Lung Disease, Inc2011 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdfAccessed August 7, 2011
   Google Scholar
• GINA – the Global Initiative for Asthma [webpage on the Internet]Global strategy for asthma management and preventionNational Heart, Lung, and Blood Institute. Global Initiative for Asthma (GINA)2010 Available from: http://www.ginasthma.org/guideline-report-2010.htmlAccessed August 7, 2011
   Google Scholar
• NHLBI, Diagnosis and Management of Asthma [webpage on the Internet]Expert Panel Report 3 (EPR3): Guidelines for the diagnosis and management of asthmaNational Heart Lung and Blood Institute updated 2012. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htmAccessed August 7, 2011
   Google Scholar
• BernsteinDIBerkowitzRBChervinskyPDose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhalerRespir Med199993960361210542973
   PubMed Web of Science ®Google Scholar
• KarpelJPNayakALumryWInhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthmaRespir Med2007101362863716875813
   PubMed Web of Science ®Google Scholar
• NoonanMKarpelJPBenschGWComparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhalerAnn Allergy Asthma Immunol2001861364311206236
   PubMed Web of Science ®Google Scholar
• DohertyDETashkinDPKerwinEEffects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPDInt J Chron Obstruct Pulmon Dis20127577122334769
   PubMed Web of Science ®Google Scholar
• TashkinDPDohertyDEKerwinEEfficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trialsInt J Chron Obstruct Pulmon Dis20127738622334770
   PubMed Web of Science ®Google Scholar
• LaForceCPrennerBMAndrianoKLavecchiaCYegenUEfficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthmaJ Asthma200542210110615871441
   PubMed Web of Science ®Google Scholar
• SinghSDWhaleCHoughtonNDaley-YatesPKirbySMWoodcockAAPharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary diseaseBr J Clin Pharmacol200355437538112680886
   PubMed Web of Science ®Google Scholar
• EdsbäckerSWollmerPSelroosOBorgströmLOlssonBIngelfJDo airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?Pulm Pharmacol Ther200821224725817950641
   PubMed Web of Science ®Google Scholar
• TrondeAGillenMBorgströmLLötvallJAnkerstJPharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPDJ Clin Pharmacol200848111300130818974284
   PubMed Web of Science ®Google Scholar
• Symbicort^® (budesonide/formaterol fumarate dehydrate) [package insert]Wilmington, DEAstraZeneca2010
   Google Scholar
• ZeidlerMCorrenJTashkinDPUse of mometasone furoate administered via a dry powder inhaler in the treatment of asthmaCurr Med Res Opin20102661295130520370376
   PubMed Web of Science ®Google Scholar
• NathanRANolteHPearlmanDSfor P04334 Study InvestigatorsTwenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroidsAllergy Asthma Proc201031426927920678306
   PubMed Web of Science ®Google Scholar
• WeinsteinSFMurphyKRCorrenJNolteHWhiteMVEfficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [abstract]J Allergy Clin Immunol2010125AB196
   Web of Science ®Google Scholar
• WeinsteinSFCorrenJMurphyKNolteHWhiteMStudy Investigators of P04431Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroidsAllergy Asthma Proc201031428028920687982
   PubMed Web of Science ®Google Scholar
• WalesDMakkerHKaneJMcDowellPO’DriscollBRSystemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteersChest199911551278128410334140
   PubMed Web of Science ®Google Scholar
• ClarkDJLipworthBJEffect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer deviceThorax199651109819848977596
   PubMed Web of Science ®Google Scholar
• MasperoJCherrezINolteHLong-term safety and tolerability of two doses of mometasone furoate/formoterol (MF/F) combination, administered via a metered-dose inhaler, for the treatment of moderate-to-severe persistent asthmaJ Allergy Clin Immunol20091232S159
   Web of Science ®Google Scholar
• MasperoJFNolteHCherrez-OjedaIP04139 Study GroupLong-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthmaJ Asthma201047101106111520874458
   PubMed Web of Science ®Google Scholar
• AdamsNBestallJJonesPBudesonide at different doses for chronic asthmaCochrane Database Syst Rev20014CD00327111687182
   PubMedGoogle Scholar
• AdamsNPBestallJCJonesPLassersonTJGriffithsBCatesCJFluticasone at different doses for chronic asthma in adults and childrenCochrane Database Syst Rev20084CD00353418843646
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP)Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence between Two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for Use in the Treatment of Asthma in Children and AdolescentsLondonEuropean Medicines Agency2009 Available from: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003504Accessed August 7, 2011
   Google Scholar